Human Growth Hormone Market Share, Size, Trends, Industry Analysis Report, By Type (Long-acting, Short-acting & Intermediate-acting); By Route of Administration; By Age; By Indication; By Distribution Channel; By Region; Segment Forecast, 2024- 2032
- Published Date:Mar-2024
- Pages: 114
- Format: PDF
- Report ID: PM4705
- Base Year: 2023
- Historical Data: 2019 – 2022
Report Outlook
Global human growth hormone market size was valued at USD 5.95 billion in 2023. The market is anticipated to grow from USD 6.62 billion in 2024 to USD 15.66 billion by 2032, exhibiting the CAGR of 11.4% during the forecast period.
Market Overview
The Human Growth Hormone (HGH) market is multifaceted, covering various aspects related to the production, distribution, and consumption of human growth hormone products. The growing trends influence a significant portion of the market scope in wellness and anti-aging. Consumers seek HGH products for potential benefits such as improved skin health, increased energy levels, and the mitigation of age-related issues, contributing to the market's expansion.
The market extends to a broad category of growth hormone supplements. These supplements may come in various forms, including pills, capsules, powders, or injections. They are tailored to meet the diverse needs of consumers, ranging from those interested in fitness and bodybuilding to individuals seeking anti-aging effects. The production and distribution of human growth hormone supplements. These supplements typically contain ingredients that aim to stimulate the body's natural production of growth hormone, offering potential benefits such as muscle growth, fat loss, and improved energy levels.
To Understand More About this Research: Request a Free Sample Report
Also, the scope of the market encompasses high supplements for men. These supplements often target male-oriented health and fitness goals, including muscle development, increased energy, and potential improvements in stamina. The market caters to the human growth hormone market demand for supplements that address men's unique requirements.
The growing prevalence of growth hormone deficiency (GHD) is the primary factor driving the human growth hormone market. Moreover, the increasing risk of other medical conditions such as metabolic syndrome, cardiovascular disease, and decreased bone mineral density owing to growth hormone deficiency is contributing to the market growth. Furthermore, the emergence of newer and innovative technologies for the improvement of patient compliance with growth hormone therapies will strengthen the market growth throughout the forecast timeframe.
The rising number of patients with pituitary dysfunction, coupled with the industry participants' focus on the development of recombinant drugs, is expected to prove beneficial for the expansion of the human growth hormone market in the upcoming years. Moreover, growing awareness related to early screening and appropriate treatment for other indications such as Turner syndrome and Prader-Willi syndrome fuels the market growth. Furthermore, an increasing FDA approval for growth hormone deficiency is expected to provide a long-term opportunity for the expansion of human growth hormone market trends.
- For instance, In June 2023, Pfizer Inc. and OPKO Health Inc. revealed that the U.S. Food and Drug Administration (FDA) approved NGENLA (somatropin-gala). This is a weekly-administered human growth hormone analog designed for the treatment of pediatric patients aged three years and above experiencing growth failure due to insufficient secretion of endogenous growth hormone.
Moreover, the adverse effects associated with human growth hormones are expected to hamper the market size growth. Furthermore, the expense of treatment with synthetic human growth hormones is also one of the major factors limiting its adoption across low and middle-income countries.
Growth Factors
Rising Prevalence of Growth Hormone Deficiency and Other Disorders
Growth hormone deficiency can be considered as a congenital or acquired medical condition that is caused by insufficient amounts of growth hormone in the body. The rising patient pool suffering from growth hormone deficiency is expected to prove beneficial for the growth of the human growth hormone market. For instance, according to the National Organization for Rare Disorders, Inc., more than 70,000 females in the U.S. are estimated to have Turner syndrome. Moreover, factors such as severe brain injuries, birth without a pituitary gland, and genetic defects are responsible for growth hormone deficiency, and thus, the demand for synthetic human growth hormone will increase in the upcoming years.
Growing Number of Research & Development Activities
The rarity of growth hormone-related diseases and their growing prevalence have increased the challenges and unmet medical needs of the patients. Rising research & development expenses by the companies owing to the presence of potential growth opportunities in the market will lead to an increasing number of product introductions in the coming years. The ongoing clinical trial studies to launch somatropin for patients suffering from growth hormone deficiency and the positive results for these pipeline products will fuel the market growth in the projected years. For instance, in December 2023, Ascendis Pharma announced positive results from a Phase III investigation of TransCon hGH (lonapegsomatropin) in adults suffering from GHD.
Restraining Factors
Side Effects and Safety Concerns
Like any medical intervention, HGH therapy is associated with potential side effects. Safety concerns, particularly in cases of misuse or unsupervised use, may restrain the market as individuals and healthcare providers carefully consider the risks and benefits. Also, the treatment of growth hormone-deficient patients with synthetic human growth hormone poses a risk of several side effects. These side effects include Carpal tunnel syndrome, Type 2 diabetes, increased insulin resistance, Joint and muscle pain, and edema, among others. Moreover, the long-term effects of HGH treatment remain unclear as the clinical trial studies on healthy older adults have been relatively small and short in duration. Such factors are expected to hinder the human growth hormone market growth during the forecast timeframe.
Report Segmentation
The market is primarily segmented based on type, route of administration, age, indication, distribution channel, and region.
|
By Type |
By Route of Administration |
By Age |
By Indication |
By Distribution Channel |
By Region |
|
|
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Type Insights
The long-acting segment is projected to expand at the highest CAGR during the forecast period.
The long-acting segment is projected to expand at the highest CAGR during the forecast period. The segmental growth is attributed to benefits such as convenience, better patient compliance, and a reduction in the frequency of administration. Moreover, a robust pipeline of investigational drugs coupled with the safety & effectiveness of long-term treatment with growth hormone injections is expected to propel segmental growth during the projected years.
By Indication Insights
The growth hormone deficiency segment accounted for the largest market share in 2023
The growth hormone deficiency segment captured the largest share of the market. The share is mainly attributed to the increasing number of patients suffering from growth hormone deficiency. Moreover, the initiatives by the government to increase awareness related to endocrine disorders and the strong focus of industry players toward the introduction of somatropin hormones for pediatrics as well as adults are contributing to the segmental share. For instance, in January 2022, Ascendis Pharma received marketing authorization from the European Commission (EC) for TransCon hGH, which is indicated for the treatment of children and adolescents between the ages of 3 to 18 years with growth hormone deficiency disease.
By Distribution Channel Insights
The hospital pharmacies segment held the largest share of the human growth hormone market in 2023
Based on the distribution channel, the hospital pharmacies segment generated the largest revenue in 2023. Factors such as the increasing number of patient visits in hospitals, favorable reimbursement scenarios, and better coordination between caregivers and patients are responsible for the significant revenue generated by this segment. Moreover, the rarity and limited awareness of human growth hormone-related diseases stimulate the patients to visit hospitals. Thus, with the increasing footfalls in hospitals, the delivery of human growth hormone from hospital pharmacies will also increase in the upcoming years.
Regional Insights
North America accounted for the largest revenue share in the human growth hormone market in 2023
North America generated the largest market revenue in 2023. The high prevalence rate of human growth hormone deficiency and Turner syndrome is one of the major factors driving the market growth in this region. Moreover, factors such as favorable reimbursement policies, huge investments in research & development activities, the strong presence of the major companies, and an increasing number of product launches are expected to fuel the market growth. For instance, in October 2021, Ascendis Pharma A/S announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd). Such availability of new products in the U.S. will contribute to the market growth in the long run.
Asia Pacific is projected to witness the highest CAGR during the forecast period.
Asia Pacific is projected to witness the highest CAGR during the forecast period. The high burden of rare genetic diseases and increasing awareness related to human growth hormone deficiency are expected to boost market growth in the coming years. Moreover, the strong focus of market players to gain product approvals in this region and rising government initiatives to offer human growth hormone medicines in various countries will fuel the market growth. For instance, in November 2023, Merck made SAIZEN (somatropin) growth hormone therapy available in Australia through the Pharmaceutical Benefits Scheme (PBS).
Key Market Players & Competitive Insights
The human growth hormone market is analyzed with the presence of few players. The key industry players are heavily investing in research & development activities to launch new products that will eliminate the limitations and side effects of currently available medications in the market. Moreover, the companies focusing on the introduction of long-acting human growth hormone are expected to witness significant growth in their share during the forecast period.
Some of the major players operating in the global market include:
- AnkeBio Co., Ltd
- Ascendis Pharma
- Eli Lilly and Company
- Ferring Pharmaceuticals
- Genentech, Inc (Roche)
- Merck KGaA
- Novartis AG
- Novo Nordisk
- Pfizer Inc.
- Sandoz International GmbH
Recent Developments in the Industry
- In April 2023, Novo Nordisk announced the approval of a new indication for Sogroya (somapacitan-beco) injection. Children who are 2.5 years of age or older and have growth failure due to insufficient endogenous growth hormone secretion are treated with this injection.
Report Coverage
The human growth hormone market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, type, route of administration, age, indication, distribution channel, and their futuristic growth opportunities.
Human Growth Hormone Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 6.62 billion |
|
Revenue forecast in 2032 |
USD 15.66 billion |
|
CAGR |
11.4% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD million and CAGR from 2024 to 2032 |
|
Segments covered |
|
|
Regional scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
FAQ's
The Human Growth Hormone Market report covering key segments are type, route of administration, age, indication, distribution channel, and region.
Human Growth Hormone Market Size Worth $15.66 Billion By 2032
Human growth hormone market exhibiting a CAGR of 11.4% during the forecast period.
North America is leading the global market
key driving factors in Human Growth Hormone Market are Growing Number of Research & Development Activities
